Logomix

Logomix Biotechnology is a San Carlos, California cellular-system-engineering company developing Geno-Writing™, a platform for rapid, precise, large-scale genome modification in human induced pluripotent stem cells. The platform translates complex digital genome designs into iPSCs for ex vivo applications, enabling the company and external partners to build engineered cellular systems for cell therapy and drug discovery. Logomix is advancing an internal Type 1 diabetes program and supports partners across disease areas; it also generates high-fidelity iPSC libraries for foundational and virtual-cell models. The company describes Geno-Writing™ as an engineering layer that closes the design-build-test loop and makes drug discovery more repeatable and scalable.